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Abstract
Background: Reverse phase protein arrays (RPPA) have been demonstrated to be a useful experimental platform
for quantitative protein profiling in a high-throughput format. Target protein detection relies on the readout
obtained from a single detection antibody. For this reason, antibody specificity is a key factor for RPPA. RNAi allows
the specific knockdown of a target protein in complex samples and was therefore examined for its utility to assess
antibody performance for RPPA applications.
Results: To proof the feasibility of our strategy, two different anti-EGFR antibodies were compared by RPPA. Both
detected the knockdown of EGFR but at a different rate. Western blot data were used to identify the most reliable
antibody. The RNAi approach was also used to characterize commercial anti-STAT3 antibodies. Out of ten tested
anti-STAT3 antibodies, four antibodies detected the STAT3-knockdown at 80-85%, and the most sensitive anti-
STAT3 antibody was identified by comparing detection limits. Thus, the use of RNAi for RPPA antibody validation
was demonstrated to be a stringent approach to identify highly specific and highly sensitive antibodies.
Furthermore, the RNAi/RPPA strategy is also useful for the validation of isoform-specific antibodies as shown for the
identification of AKT1/AKT2 and CCND1/CCND3-specific antibodies.
Conclusions: RNAi is a valuable tool for the identification of very specific and highly sensitive antibodies, and is
therefore especially useful for the validation of RPPA-suitable detection antibodies. On the other hand, when a set
of well-characterized RPPA-antibodies is available, large-scale RNAi experiments analyzed by RPPA might deliver
useful information for network reconstruction.
Background
Reverse phase protein arrays
The potential use of the RPPA technology in the field of
proteomics and systems biology was introduced in 2001
by Paweletz and colleagues [1]. Since then, the RPPA
technology has been further advanced, and successfully
applied in numerous proteomic studies [2-13]. The basic
principle of RPPA follows the idea of a dot-immunoblot;
large numbers of samples are arrayed on solid phase car-
riers, and each array can then be probed with a different
highly specific antibody. RPPA provide a semi-quantita-
tive readout, and the expression of a particular target
protein can be compared among all samples printed on a
particular array. Printing of numerous replicate slides
permits access to a highly parallelized analysis since each
slide can be probed with a different detection antibody.
Characterization of antibody specificity for RPPA
applications
The outcome of all types of immunoassays strongly
depends on antibody specificity and affinity. These fac-
tors are far more important for RPPA compared to
other immunoassays such as Western blotting (WB),
immunohistochemistry (IHC) or sandwich ELISA/
microspot immunoassay (MIA). In detail, in Western
blot experiments, unspecific binding of antibodies can
frequently be identified by taking into account the
reported molecular weight (MW) of a certain target pro-
tein. Similarly, in IHC experiments, antibody cross-
reactivity can be identified by paying attention to the
expected cellular or sub-cellular localization of a certain
target protein. For antibodies used in sandwich MIA
and in ELISA, a slight cross reactivity can be tolerated if
the off-target binding properties of the two antibodies
do not overlap. In contrast, antibody specificity for
RPPA experimentation has to be assessed separately and
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by Western blot is a commonly accepted strategy
[1,7,14]. However, even those antibodies showing mono-
specificity on Western blot as well as a linear correlation
between the signal intensity and the corresponding dilu-
tion step of serially diluted samples do not always quan-
tify the corresponding target proteins correctly. Even
minor unspecific binding contributes to the signal of a
certain spot on RPPA. Furthermore, since RPPA are a
high-throughput tool with totally or partially automated
incubation protocols, it is not possible to optimize the
incubation conditions for individual antibodies as com-
mon in Western blot strategies, and experimental condi-
tions are chosen to work for the majority of RPPA
antibodies. Interactions between an epitope of a target
protein and the corresponding paratope of the antibody
are influenced by small experimental changes of pH,
temperature, ion concentration or detergents. Similarly,
target protein conformation, sample pretreatment, and
composition of the protein matrix influence the interac-
tion between an epitope and its paratope. Considering
all these parameters, it is comprehensible that Western
blot results do not necessarily correspond with RPPA
outcome. Nevertheless, Western blot will remain an
indispensable tool for the characterization of antibody
specificity, and is also used for antibody validation in
the approach introduced here.
RNA interference
RNA interference (RNAi) is a biological process where
small RNA molecules silence gene expression, either by
inducing sequence specific degradation of target mRNA
or by inhibiting translation [15]. After its first discovery
by Fire and Mello in C. elegans [16] and the proof that
this mechanism can be exploited for the manipulation
of mammalian cells [17], RNAi opened up a new era in
reverse genetics and enabled large-scale loss-of-function
studies. Chemically synthesized small interfering RNA
(siRNA) molecules have been shown to be potent effec-
tors of post-transcriptional gene silencing and result in
the specific inhibition of protein expression. For this
reason, RNAi is considered as one of the most promis-
ing tools to dissect biological processes. We have pre-
viously applied RPPA to quantify protein expression
after applying multiple siRNAs simultaneously [18], as
well as to reconstruct protein networks by quantifying
proteins of a given network after a knockdown of
selected proteins [19,20].
The potential of RNAi to validate antibodies for RPPA
applications
Positive controls for the validation of phospho-specific
antibodies can easily be generated by treating a cell line
with UV light or growth factors [21]. By this way,
suitable controls can be generated to discriminate
between phosphorylated and non-phosphorylated forms
of a certain protein. However, positive controls for gen-
eral target protein-specific antibodies require either the
elimination of a certain protein from a complex mixture
or the introduction of the protein of choice into a suita-
ble matrix to mimic the biological context. Likewise,
this strategy can also be applied to characterize protein
isoform-specific antibodies. Moreover, the limit of detec-
tion (LOD) might be of interest for quantitative RPPA
applications which can be determined by using a spike-
in approach. However, when performed on a larger
scale for numerous targets the spike-in strategy would
require access to large numbers of purified and well-
characterized proteins. Recombinant proteins are fre-
quently tedious to obtain and heterologously produced
recombinant proteins are not necessarily recognized by
antibodies with an affinity and specificity comparable to
endogenous protein. An alternative strategy might be
RNAi; first, to validate the specificity of antibodies and,
secondly, to determine the LOD of specific antibodies.
For this reason, serial dilutions of siRNA-treated sam-
ples and untreated samples as controls were printed in
parallel onto nitrocellulose-coated slides which were
probed with a panel of different detection antibodies
directed against the target protein of choice. In addition,
the knockdown efficiency was determined in parallel by
Western blot. Antibodies which detected the reduced
abundance of the targeted protein in siRNA-treated
samples and with a rate comparable to that measured
by Western blot were considered as suitable for use in
RPPA applications.
Results
Antibody validation using quantitative Western blot
Antibody specificity was initially assessed by Western
blot. For example, figure 1 shows the detection of EGFR
in MDA-MB-231 cell lysates by two different anti-EGFR
antibodies. In detail, both antibodies recognized the pre-
dominant band of (~175 kDa) molecular weight, corre-
sponding to the reported size of EGFR, and a weak low
molecular weight band of approximately 60 kDa. Next,
EGFR was knocked-down by RNAi in MDA-MB-231
cells and quantified by Western Blot (figure 2). To cal-
culate the knockdown rate, a linear regression was cal-
culated on the median of a five-step MDA-MB-231
dilution series, and slope and intercept were used to
determine the relative concentration of EGFR protein in
the positive controls as well as in the siEGFR transfected
samples. Both antibodies indicated that EGFR abun-
dance was reduced by 80% as a result of EGFR silencing.
Figure 2 illustrates that specificity and quantitative data
obtained for both anti-EGFR antibodies by Western blot
were comparable. However, the EGFR signal obtained
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probing with antibody 1.
Antibody validation on RPPA
To compare the knockdown quantification capacity of
the two anti-EGFR antibodies on RPPA, the MDA-MB-
231 dilution series was spotted along with dilution series
prepared from siRNA-treated samples. The knockdown
efficiency was quantified as described for the Western
blots. On RPPA antibody 1 detected a reduced target
protein expression rate of ~60% whereas antibody 2
detected a reduced expression rate of 85%, and the latter
v a l u ew a sa l s oo b t a i n e db yW e s t e r nb l o t( f i g u r e3 ) .
Furthermore, whereas on Western blot the dynamic
range of both antibodies differed by a factor of two, the
difference increased further to almost an order of mag-
nitude on RPPA. Samples were printed in replicate on
three different slides along with two independent dilu-
tion series were used to calculate the knockdown effi-
ciency (Table 1). A Pearson correlation coefficient of
greater than 0.99 indicated that the RPPA approach is
technically robust (figure 4). To sum up, anti-EGFR
antibody 2 detected the reduced abundance of EGFR in
the knockdown sample at a higher rate than antibody 1,
indicating that the signal obtained from antibody 1
might be obscured by weak cross reactivity with other
proteins which was not noticed in the Western blot Figure 1 Target specificity of anti-EGFR antibodies.T w o
different anti-EGFR antibodies were compared by Western blot to
detect endogenous EGFR in MDA-MB-231 cell lysate before and
after siRNA-induced knockdown.
Figure 2 Knockdown detection capacity of anti-EGFR
antibodies. EGFR levels of siALLSTAR and siEGFR transfected MDA-
MB-231 cells were quantified using two anti-EGFR antibodies and a
linear regression model fitted on a serially diluted MDA-MB-231 cell
lysate. Both antibodies showed identical readout for Western Blot-
based knockdown quantification.
Figure 3 RPPA quantification of EGFR knockdown.T w o
biological samples and four control samples were printed on
nitrocellulose coated slides (four technical replicates per sample).
Signal detection was performed using NIR-fluorescent dye labeled
secondary antibodies. Position of siEGFR (green) and siALLSTAR
(blue) transfected samples is indicated (A). Spots are false color
images of fluorescent signals. None of the signals reached the
saturation range of the scanning instrument (Odyssey, LI-COR).
Target protein knockdown was determined by comparing EGFR
signal intensity between siEGFR and siAllstar transfected samples.
The linear regression was calculated from a dilution series of whole
cell lysate from MDA-MB-231 cells (B).
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more appropriately for RPPA applications.
Signal intensity is independent from knockdown
quantification rate
To assess a general applicability of RNAi for RPPA anti-
body validation the approach was validated on a larger
set of antibodies. In detail, ten commercially available
antibodies against STAT3 obtained from different sup-
pliers were compared (Additional file 1 Table S1). The
set of ten anti-STAT3 antibodies was selected based
defined applications; only antibodies of the IgG type,
generated in mouse or rabbit, recommended for Wes-
tern blot as well as immuno-precipitation, and adver-
tised as being specific for the detection of the human
STAT3 protein were chosen. While anti-STAT3 antibo-
d i e s1a n d2d e t e c t e dad o u b l eb a n d( f i g u r e5 A )o n
Western blot, antibodies 3-6 revealed a single band of
the expected size. Antibody 7 produced a predominant
specific band and several weak but unspecific bands.
Antibodies 8-10 were considered as unspecific as they
detected several additional and obviously unspecific
bands by Western blot.
In the EGFR-antibody example, the EGFR-knockdown
was recognized less efficiently by the weaker antibody.
Thus, the question whether the signal intensity range
could possibly be related to the RPPA outcome was
addressed experimentally using the set of ten STAT3
antibodies. Figure 5B summarizes the RPPA signal
dynamics of all ten anti-STAT3 antibodies. For nine
antibodies, a strict correlation between signal intensity
and total protein concentration was observed. Signals
from antibody 6 were comparable to the background
signals obtained in control incubations without primary
antibody. Signal ratios were different for the remaining
set of nine anti-STAT3 antibodies, and none of the anti-
bodies reached signal saturation. In general, rabbit poly-
clonal antibodies displayed significantly stronger signals
than mouse monoclonal antibodies. A linear correlation
between signal intensity and protein concentration was
observed for the nine anti-STAT3 antibodies over a
>20-fold concentration range. To demonstrate that
RPPA signals are target protein-specific, a STAT3-
knockdown was quantified by probing each of the anti-
STAT3 antibodies on separate arrays. The concentration
of STAT3 was calculated for knockdown samples and
controls as described for EGFR and table 2 summarizes
the data. Those antibodies showing multiple bands cor-
responding to the molecular weight of STAT3 (AB 8-
10) on Western blot detected the knockdown at a rate
between 32 and 57% while the specific antibodies 1-5
identified the STAT3 knockdown at a rate ranging
between 69 and 86%. Moreover, antibody 7, which
shows additional faint low molecular weight bands by
Western blot, quantified the STAT3 knockdown at a
rate of 80%. Finally, anti-STAT3 antibodies 1-5 and 7
detected the STAT3 knockdown at a rate > 69%. Knock-
down detection and RPPA signal dynamics were corre-
lated in Figure 6. The correlation coefficient indicates
that the signal dynamics and specificity are not directly
connected with each other; antibody with weak signaling
dynamics can recognize their target protein with high
specificity.
Introducing the detection limit as criterion for RPPA
antibody validation
Four out of ten anti-STAT3 antibodies (AB 2, 3, 4, and 7)
detected the knockdown of STAT3 at a rate ranging
between 80 - 86%, and at a rate comparable to that
detected by Western blot. Next, the detection limit was
determined to identify the most sensitive antibody. For
this, the median signal intensity as well as the median
absolute deviation (MAD) was calculated from the read-
i n g so fb l a n ks p o t sf o re a c ho ft h ef o u ra n t i - S T A T 3
Table 1 EGFR knockdown efficiency determined by RPPA
Antibody
a Calibrator
b Array
c
123
EGFR #1 1 59% 60% 61%
2 58% 58% 60%
EGFR #2 1 85% 85% 84%
2 85% 85% 84%
a Two different anti-EGFR antibodies (#1, #2) were used to quantify the EGFR
knockdown.
b Each subarray contained two different calibrator dilution series (1, 2) printed
in parallel with biological replicates of the EGFR knockdown and controls.
c Three different subarrays (1-3) were printed and analyzed. Quantitative
readout calculated in percent based on signals from control transfections with
non-targeting siRNAs.
Figure 4 Technical robustness of RPPA based knockdown
detection. Three replicate arrays with EGFR knockdown samples
were probed with two different antibodies targeting EGFR (anti-
EGFR 1 and -2). The plots show the correlation analysis for the
different combinations and provide a Pearson correlation coefficient
(R2) for the different comparisons.
Mannsperger et al. Proteome Science 2010, 8:69
http://www.proteomesci.com/content/8/1/69
Page 4 of 10antibodies. Next, the limit of detection was calculated
from the median of the blank spots by adding five times
the MAD of the respective antibody (median signal
intensities for blank spots ranged from 8 [au] for anti-
body 4 to 200 [au] for antibody 8). Next, a linear regres-
sion model was fit on the serial dilutions of the positive
controls to calculate the detection limit of each antibody
(Table 2). Anti-STAT3 antibody 4 still detected
endogenous STAT3 at a total protein concentration
when the MDA-MB 231 cell lysate was diluted down to
0.017 μg/μl and was identified as the most sensitive anti-
body. Antibody 1 and antibody 7 were ranked second
and detected endogenous STAT3 down to a total protein
concentration of 0.030 μg/μl MDA-MB 231 cell lysate,
and antibody 3 required almost twice the amount of total
protein and was the least sensitive antibody.
Figure 5 Target specificity and signal/concentration ratio of STAT3 antibodies. Ten antibodies targeting STAT3 were tested on lysates of
MDA-MB-231 cells by Western blot. Antibodies 1-6 showed high specificity whereas antibodies 7-10 detected additional bands of lower
molecular weight (A). RPPA signal dynamics of STAT3 antibodies probed on lysates of MDA-MB-231 cells (B).
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To demonstrate that the RNAi-based strategy of anti-
body validation is also suitable for the identification of
isoform-specific antibodies, two pairs of highly homolo-
gous target proteins were chosen to proof this in princi-
ple. In detail, two members of the cyclin family, CCND1
(cyclinD1) and CCND3 (cyclinD3) as well as AKT1 and
AKT2 were knocked-down by RNAi and detected with
antibodies supposed to recognize specifically the corre-
sponding isoforms. Beforehand, the Needleman-Wunsch
algorithm was applied to determine the degrees of simi-
larity as well as of identity: The cyclins show an identity
ratio of 51.7% and a similarity ratio of 67% whereas the
AKT proteins are more closely related and revealed
81.1% sequence identity and 91.9% similarity. Silencing
was performed for 48 h and the experimental data were
analyzed by RPPA and summarized as ordered heatmap
(figure 7A). Thus, the data demonstrated a specific
detection of all four proteins as indicated by the blue
color. All four antibodies distinctly detected the knock-
down of the respective target protein, and none of them
revealed cross reactivity with its homologous counter-
part. Even the highly related proteins AKT1 and AKT2
were detected specifically. Figure 8 shows data from the
corresponding qRT-PCR analysis confirming a downre-
gulation of the targeted transcripts (figure 7A).
Benefits of RNAi-based antibody validation for clinical
and basic research
As shown for a set of only four targets proteins, the use
of highly specific RPPA-validated antibodies in combina-
tion with the targeted knockdown of selected proteins
provided quantitative data which were useful to dissect
regulatory edges in signaling networks. Thus, proteomic
data can in principle aid network reconstruction and the
elucidation of coregulation and codependencies. To
illustrate the potential of this approach, the impact of a
knockdown of 27 different proteins on the AKT1
Table 2 Quantification of STAT3 knockdown and
determination of STAT3 detection limits
Antibody Knockdown efficiency LOD [μg/μl]
b
1
a 2
a 1
a 2
a
AB1 75% 74% 0.027 0.033
AB2 82% 81% 0.035 0.038
AB3 86% 85% 0.057 0.057
AB4 84% 83% 0.016 0.018
AB5 69% 68% 0.029 0.031
AB6 -2% -3% 0.173 0.134
AB7 80% 80% 0.031 0.030
AB8 32% 33% 0.073 0.057
AB9 57% 56% 0.077 0.077
AB10 53% 52% 0.023 0.023
a Two different MDA-MB231 dilution series (1, 2) were used to calculate the
percentage of the STAT3 knockdown.
b The limit of detection (LOD) was calculated for AB1-10 and is expressed as
μg/μl MDA-MB231 lysate.
Figure 6 Comparing antibody signal dynamics and
quantitative readout after STAT3 silencing. The RPPA signal
range of six highly specific anti-STAT3 antibodies was correlated
with the quantitative readout obtained for each of the respective
antibodies when applied for the RPPA analysis of STAT3-silencing
(R
2). The data set was calculated twice by using each of the two
independent calibrator dilution series (black and grey). The
correlation coefficient was calculated using MS Excel, the linear
regression line was added.
Figure 7 Determination of isoform-specificity by RNAi and its
application for network analysis. AKT 1 and AKT 2 as well as
cyclin family members CCND1 and CCND3 were knocked down
individually and the protein levels were then detected specifically
by RPPA. Low protein levels are represented in blue and high levels
in red (A). The 27 indicated genes were knocked down individually
with specific siRNAs and the effect on AKT1 protein levels was
measured using an isoform-specific antibody. The heatmap section
shows a reduced (blue) or elevated expression (red) of AKT1 in
response to a targeted knockdown of the 27 genes (B).
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body clearly identified the AKT1 knockdown sample.
The abundance of AKT1 was not influenced by the
majority of siRNA-targeted proteins including also the
knockdown of AKT2 which was already seen in figure
7A. In contrast, the knockdown of MAPK14 resulted in
as t r o n gi n c r e a s eo fA K T 1a b u n d a n c eo nt h ep r o t e i n
level. This observation is presumably well in line with
biology as the opposite event, the AKT-mediated down
regulation of p38 signaling was reported to occur in
endothelial cells [22].
Discussion
Several studies presented antibody validation methods
for use in immune-histochemistry [23,24] stating that
thorough testing of antibodies is mandatory [24].
Accordingly, we have demonstrated here that using
Western blot approaches for antibody characterization is
not sufficient for the identification of RPPA-suitable
antibodies. In contrast, a combination of targeting those
proteins which are presumably recognized by the anti-
bodies of choice by siRNA permitted a thorough valida-
tion of antibody specificity.
All antibodies tested in this study were commercially
available and were obtained from different suppliers.
The knockdown of STAT3 or EGFR by RPPA was gen-
erally detected with high specificity but differing quanti-
tative readout. Monoclonal antibodies are directed
against single epitopes, and the peptide sequence recog-
nized by a specific antibody might be inaccessible under
the native conditions of the RPPA. Furthermore, highly
specific monoclonal Western blot antibodies do not
necessarily work equally well on RPPA. For example,
although STAT3 antibody 5 detected a single band on
Western blot, the STAT3 knockdown was quantified at
a rate of only 69% whereas other antibodies determined
the STAT3-knockdown in the range of 80-85%. On the
other hand, anti-STAT3 antibody 7 revealed cross
reactivity on Western blot but demonstrated high speci-
ficity on RPPA with a STAT3-knockdown rate of 80%.
Western blot and RPPA are for several reasons not
directly comparable. First of all, different buffers were
used for sample preparation which might influence the
display of protein epitopes. Moreover, unpurified and
crude samples are exposed to antibody-based detection
on RPPA whereas the SDS-PAGE-based sample separa-
tion might remove certain impurities. For example, cel-
lular debris does not enter the separation gel whereas
degraded protein leave the gel quickly and are poten-
tially eluted into the SDS-PAGE running buffer. Besides
that, the velocity of electrophoretic transfer during the
Western blot procedure depends on the charge as well
as the size of a certain protein, e.g. small proteins are
transferred faster and might be eluted into the Western
blot transfer buffer whereas very large proteins might
remain in the gel. In conclusion, the exact quantification
of RNAi-based knockdown in biological samples pre-
sents a reliable strategy for the characterization of anti-
body properties for RPPA applications. The chances to
detect a false negative result after performing a silencing
experiment were considered as unlikely especially since
appropriate control experiments were performed and
analyzed in parallel.
RPPA are customized assays and are used in different
experimental setups with respect to sample preparation
and target protein detection. Loebke and colleagues
used near-infrared (NIR) labeled secondary antibodies
for signal detection on RPPA and employed a native
lysis protocol to avoid protein denaturation [11]. Tibes
and colleagues printed denatured samples and visualized
the protein concentration using enzyme-based signal
amplification with colorimetric readout (DAKO cytoma-
tion) [13], while Berg and colleagues collected samples
from formalin fixed samples and detect the proteins by
ECL [6]. Even other combinations of samples and detec-
tion methods can be envisioned. The diversity in the
experimental setup of RPPA applications requires a
proper validation of antibodies for a specific protocol
and the biological context. The approach presented here
will most likely also be useful for other RPPA setups
since it allows the assessment of antibody specificity in a
certain biological context and independently from sam-
ple preparation protocol and detection method. Further-
more, the strategy presented here could also be applied
to the characterization of alternative protein binders
such as Darpins (ankyrin repeat proteins) [25]. Quantifi-
cation of protein activation or inhibition within a parti-
cular signaling network is another promising RPPA
application which requires availability of phospho-speci-
fic antibodies [21] and demands also tools for efficient
antibody validation. Silencing of endogenous proteins is
superior over using a spike-in recovery of recombinant
Figure 8 Knockdown validation using quantitative real time
PCR. Knockdown of AKT1 and AKT2 as well as CCND1 and CCND1
mRNAs upon siRNA transfection into MDA-MB-231 cells was
measured by quantitative real-time PCR. Respective siRNAs applied
in the transfection are indicated in relation to the relative mRNA
expression levels (values normalized to non-targeting controls ACTB
and HPRT mRNAs).
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proteins might be different from the recombinant
proteins due to changes of protein folding, aberrant dis-
ulfide bridge formation, and the lack of suitable post-
translational modification or the introduction of new
modifications. Nevertheless, RPPA can be used to quan-
tify robustly the impact of a particular treatment on tar-
get protein regulation for both directions, up- as well as
downregulation, especially when signal detection is per-
formed with fluorescent dyes in the NIR range since
rarely signal saturation is reached. Antibodies detecting
multiple bands on Western blot are not necessarily
unspecific but might recognize proteins regulated by
post-translational modification, breakdown products, or
splice variants. In such cases, the method introduced
here will provide evidence for the specificity of an anti-
body that could not be clarified otherwise.
The isoform-specific detection of proteins within sig-
naling networks is required for the unambiguous identi-
fication of an individual contribution to highly regulated
signaling processes. Since is o f o r m so fp r o t e i n sf r e -
quently express highly homologues peptide sequences,
antibody specificity is of utmost importance for this
application. Our data suggest that the siRNA-mediated
antibody validation approach is highly capable to test
the specificity of antibodies and especially useful to
characterize antibodies which presumably recognize a
particular isoform. On the other hand, this approach
can thus provide key information on the regulation of
protein networks to unravel signaling networks. There-
fore, this validation method will extend the practical
applicability of the RPPA technology in the field of sys-
tems biology and will open up new prospects for pro-
teome research.
Conclusions
We have introduced a new antibody validation approach
which is based on a targeted knockdown strategy and
subsequent quantification of the proteins of interest to
quantify the difference between endogenous and residual
target protein abundance by RPPA. Employing a tar-
geted knockdown strategy we have demonstrated the
potential of our approach to identify and validate anti-
bodies that are able to distinguish highly homologous
isoforms and to generate systems level information use-
ful for protein network analysis.
Methods
Cell culture and siRNA transfection
The human breast cancer cell line MDA-MB-231 (HTB-
26) was obtained from ATCC (Manassas, VA, USA). Cells
were cultured in Leibovitz’s L-15 medium (Sigma, St
Louis, MO, USA) and supplemented with 50 U/mL peni-
cillin, 50 μg/mL streptomycin sulphate, 1% non-essential
amino acids, 10% fetal bovine serum (Gibco-BRL,
Bethesda, MD, USA) and 3 g/L sodium bicarbonate
(AppliChem, Darmstadt, Germany). MDA-MB-231 cells
were seeded in 6-well format at 2 × 10
5 cells/well and cul-
tivated for 24 h at 37°C and 5% CO2. Prior to transfection,
medium was replaced with antibiotics-free medium. Cells
were transfected with siRNAs targeting EGFR, STAT3,
AKT1, AKT2, CCND1,a n dCCND3 purchased from Dhar-
macon (Lafayette, CO, USA). For each gene, four indivi-
dual siRNAs were pooled (Additional file 2 Table S2).
Allstar siRNA (Qiagen, Hilden, Germany) was used as
non-silencing control. siRNAs were transfected by using
Lipofectamine 2000 (Invitrogen, CA, USA) at a final con-
centration of 20 nM and cells were harvested after 48 h of
further incubation.
Quantitative real time PCR
Total RNA from MDA-MB-231 was extracted by using
the RNeasy Mini Kit (Qiagen, Hilden, Germany). cDNA
was generated with the Revert Aid H Minus First Strand
cDNA Synthesis Kit (Fermentas St. Leon-Rot, Germany)
using 0.5 μg oligo (dT) primers with 2 μlo ft o t a lR N A .
mRNA quantification of the target and housekeeping
genes ACTB and HPRT was performed with ABI Prism
7900HT Sequence Detection System (Applied Biosystems,
Weiterstadt, Germany) using probes of the Universal
Probe Library (Roche, Penzberg, Germany). Primer
sequences and matching UPL probe numbers are given in
Additional file 3 Table S3. Data was analyzed with the
ddCt algorithm (Bioconductor package) and mRNA levels
were normalized to the level of the housekeeping genes.
Cell lysis and Western blotting
Samples were trypsinized from the cell culture dish; cells
were pelleted and stored at minus 80°C until lysis. The
lysis buffer (MPER, Thermo Scientific) was supplemen-
ted with protease inhibitor (miniComplete, Roche). Cells
were suspendend in 25 μl of lysis buffer and lysed for
20 min at 4°C on a rotating wheel. After centrifugation,
approximately 25 μl of protein extract was obtained
from a single well. Protein concentration was deter-
mined using a modified BCA protein assay [26] (Pierce,
Bonn, Germany). Samples were mixed with standard
protein loading buffer (2×) (Roth, Karlsruhe, Gemany)
and heated for 5 min at 95°C. Proteins were subjected
to electrophoretic separation at 125 mV for 75 min and
transferred in a semi-dry approach on PVDF membrane
for 60 min at 25 mV. The membrane was blocked for
6 0m i ni nO d y s s e yb l o c k i n gb u f f e r / P B S( 5 0 %v / v ) .
Detection antibodies were diluted 1:1000 into blocking
buffer and incubated on the membrane over night at
4°C. Unbound primary antibody was removed by carry-
ing out 5 washing cycles with 0.1% (v/v) Tween/PBS.
Secondary NIR-dye labeled antibodies were diluted
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membrane for 1 hour at RT. For signal detection, mem-
branes were scanned using the Odyssey imaging system
(LI-COR Biosciences, Lincoln, USA).
Reverse phase protein array
The total protein concentration was adjusted to 3 μg/μl
for samples >3.3 μg/μl, and left unchanged for concentra-
tions below this value. All sampled were transferred to a
384-well plate. Tween was added to result in a final con-
centration of 0.05% (w/v). Using an Aushon 2470 micro-
arrayer (Billerica, MA) equipped with 185 μms o l i dp i n s
approximately 1.6 nl sample was delivered per spot onto
nitrocellulose coated slides (Oncyte Avid, Grace Bio-labs,
Bend, OR, USA). Samples were printed in three subarrays
per slide and in four replicate spots. Slides were stored at
-20°C. To estimate the total protein concentration per
spot a slide from each print run was stained with Fast
Green FCF (Sigma-Aldrich, Steinheim, Germany) as
described before [11]. Slides were mounted in a custo-
mized incubation chamber (Metecon, Mannheim,
Germany) to form three individual incubation chambers
on top of each subarray. Prior to antibody staining, arrays
were blocked for 1 h at RT with 50% (v/v) Odyssey block-
ing buffer in PBS. Slides were then incubated with target
protein specific antibodies diluted 1:300 in blocking buf-
fer at 4°C over night. After washing the slides, secondary
antibodies were diluted 1:8000 in PBS with 0.05% Tween
and incubated for 1 h at RT. Finally, slides were washed,
the chamber was unmounted and air dried.
Data analysis
Slides were scanned at 21 μmr e s o l u t i o no na nO d y s s e y
scanner (LI-COR, Lincoln, NB, USA) and images were
saved as 16 bit gray scale TIF files. Analysis of the TIF
files was performed using GenePix Pro 5.0 microarray
analysis software (Molecular Devices, Silicon Valley, CA,
USA). Data analysis was done using R and the package
RPPanalyzer [27]. For each antibody the logged mean
pixel intensity of a single spot was subtracted by the cor-
responding Fast Green FCF signal to normalize for the
total protein immobilized per spot. Knockdown recovery
was calculated by fitting a linear model on the calibrator
dilution series, the virtual concentration of the knock-
down samples, and the control transfection samples was
calculated using the coefficients of the linear model.
Additional material
Additional file 1: Table S1. Antibodies used for RPPA detection.
Table summarizes information provided by antibody suppliers; antibody
names, order number, supplier, host used to produce the antibody,
antibody type, epitope/domain recognized (if known), certified
applications, species specificity.
Additional file 2: Table S2. Sequences of siRNAs targeting AKT1,
AKT2, CCND1 and CCND3. Table lists the exact sequence of the four
siRNAs which were used per targeted transcript.
Additional file 3: Table S3. Primer Sequences used in TaqMan
assays. Table lists 5’ and 3’ specific primers used in qPCR reactions with
reference to the UPL probe number.
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